Literature DB >> 6749471

Short-course therapy for tuberculosis.

M Aquinas.   

Abstract

The discovery of rifampicin was the turning point away from the standard long term treatment for tuberculosis of 18 to 24 months and towards a 6-month curative programme. Rifampicin has proven to be highly effective and vital to short-course tuberculosis therapy, but its disadvantage is its cost. This makes it relatively unavailable where it is most needed, i.e. in countries where tuberculosis is still rampant, but which are economically underdeveloped. In such areas other needs take precedence over a chronic and non-spectacular medical condition like tuberculosis. During the past 10 years pyrazinamide has been 'rediscovered' and restudied, and when used in combination with rifampicin has been shown to play an important role in short-course chemotherapy. Its contribution to efficacy does not appear to extend beyond the first 2 months of therapy, and it should be discontinued after 2 months. This relatively short administration period helps to minimise adverse reactions to the drug. The main measure of success in short-course chemotherapy is the relapse rate, and this has been higher, sometimes unacceptably so, in regimens where bacteriostatic drugs were substituted for bactericidal ones. In conclusion, isoniazid, rifampicin and pyrazinamide in combination may be deemed essential to an effective short-course regimen of 6 months' duration. Curtailing the duration of treatment to less than 6 months in smear-positive tuberculosis results in high relapse rates and thus is not acceptable. Several studies have been undertaken varying the drug combinations, the dosages and the drug administration routines (i.e. whether daily followed by intermittent or intermittent throughout), in an effort to arrive at the simplest, most effective, least toxic and most economical all-round treatment programme. Such studies are still in progress. When recommended dosage regiments are followed, the incidence of adverse reactions is low with short-course therapy, and in only 5% or less of patients is it necessary to withdraw one or more drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6749471     DOI: 10.2165/00003495-198224020-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  22 in total

1.  Two three-month treatment regimens for pulmonary tuberculosis.

Authors:  B Kreis; S Pretet; J Birenbaum; P Guibout; J J Hazeman; E Orin; S Perdrizet; J Weil
Journal:  Bull Int Union Tuberc       Date:  1976

2.  Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils.

Authors: 
Journal:  Lancet       Date:  1974-08-03       Impact factor: 79.321

3.  Sputum-smear-negative pulmonary tuberculosis: controlled trial of 3-month and 2-month regimens of chemotherapy.

Authors: 
Journal:  Lancet       Date:  1979-06-30       Impact factor: 79.321

4.  Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1977-07

5.  Rifampin in initial treatment of pulmonary tuberculosis. A.U.S. Public Health Service tuberculosis therapy trial.

Authors:  R Newman; B E Doster; F J Murray; S F Woolpert
Journal:  Am Rev Respir Dis       Date:  1974-02

6.  Tuberculosis chemotherapy practices in major metropolitan health departments in the United States.

Authors:  A R Leff; D R Leff; A Brewin
Journal:  Am Rev Respir Dis       Date:  1981-02

7.  A service program of antituberculosis chemotherapy with five drugs for four months in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong. Hong Kong Chest Service/British Medical Research Council.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1980-09

Review 8.  Transmission of tubercle bacilli: The effects of chemotherapy.

Authors:  A Rouillon; S Perdrizet; R Parrot
Journal:  Tubercle       Date:  1976-12

9.  Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis.

Authors: 
Journal:  Lancet       Date:  1981-01-24       Impact factor: 79.321

10.  A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association.

Authors: 
Journal:  Br J Dis Chest       Date:  1981-04
View more
  5 in total

Review 1.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

Review 2.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

3.  Intensive short-course chemotherapy in pulmonary tuberculosis.

Authors:  A Rakhit; P G Khandelwal; S K Mukherjee; A K Dey
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

4.  Production and characterization of a highly pure RNA polymerase holoenzyme from Mycobacterium tuberculosis.

Authors:  Omar Herrera-Asmat; Lucyna Lubkowska; Mikhail Kashlev; Carlos J Bustamante; Daniel G Guerra; Maria L Kireeva
Journal:  Protein Expr Purif       Date:  2017-03-18       Impact factor: 1.650

Review 5.  Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis.

Authors:  Erik J Hasenoehrl; Thomas J Wiggins; Michael Berney
Journal:  Front Cell Infect Microbiol       Date:  2021-01-11       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.